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Abstract
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary
artery disease. However, despite increasing use of statins, a significant number of coronary events
still occur and many of such events take place in patients presenting with type 2 diabetes and
metabolic syndrome. More and more attention is being paid now to combined atherogenic
dyslipidemia which typically presents in patients with type 2 diabetes and metabolic syndrome. This
mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein
cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an
accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B) – emerged
as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for
cardiovascular disease. Most recent extensions of the fibrates trials (BIP – Bezafibrate Infarction
Prevention study, HHS – Helsinki Heart Study, VAHIT – Veterans Affairs High-density lipoprotein
cholesterol Intervention Trial and FIELD – Fenofibrate Intervention and Event Lowering in
Diabetes) give further support to the hypothesis that patients with insulin-resistant syndromes such
as diabetes and/or metabolic syndrome might be the ones to derive the most benefit from therapy
with fibrates. However, different fibrates may have a somewhat different spectrum of effects. Other
lipid-modifying strategies included using of niacin, ezetimibe, bile acid sequestrants and cholesteryl
ester transfer protein inhibition. In addition, bezafibrate as pan-peroxisome proliferator activated
receptor activator has clearly demonstrated beneficial pleiotropic effects related to glucose
metabolism and insulin sensitivity. Because fibrates, niacin, ezetimibe and statins each regulate
serum lipids by different mechanisms, combination therapy – selected on the basis of their safety
and effectiveness – may offer particularly desirable benefits in patients with combined
hyperlipidemia as compared with statins monotherapy.
Review
Lowering of low-density lipoprotein (LDL) cholesterol
with 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) is clearly efficacious in the treatment
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and prevention of coronary artery disease (CAD) [1-8].
However, despite increasing use of statins, a significant
number of coronary events still occur and many of such
events take place in patients presenting with type 2 diabe-
tes and metabolic syndrome. More and more attention is
being paid now to combined atherogenic dyslipidemia
which typically presents in patients with type 2 diabetes
and metabolic syndrome [9]. This mixed dyslipidemia (or
"lipid quartet"): hypertriglyceridemia, low HDL (high-
density lipoprotein)-cholesterol levels, a preponderance
of small, dense LDL particles and an accumulation of cho-
lesterol-rich remnant particles (e.g. high levels of apolipo-
protein B) – emerged as the greatest "competitor" of LDL-
cholesterol among lipid risk factors for cardiovascular dis-
ease. The lifestyle changes recommended by the National
Cholesterol Education Program (NCEP) Adult Treatment
Panel (ATP) III for controlling dyslipidemia (i.e., elevated
levels of triglycerides and decreased levels of HDL-choles-
terol) in patients with metabolic syndrome or type 2 dia-
betes mellitus (DM) include (1) reduced intake of
saturated fats and dietary cholesterol, (2) intake of dietary
options to enhance lowering of low-density lipoprotein
cholesterol, (3) weight control, and (4) increased physical
activity. If lifestyle changes are not successful for individ-
uals at high risk of developing CAD, or for those who cur-
rently have CAD, a CAD risk equivalent, or persistent
atherogenic dyslipidemia, then pharmacotherapy may be
necessary. Current therapeutic use of statins as mono-
therapy even in optimal doses and achieved target LDL-
cholesterol reduction is still leaving many patients with
mixed atherogenic dyslipidemia at high risk for coronary
events. Targeting multiple lipid pathways can provide
greater reductions in LDL-C as well as improvements in
other lipid parameters. In the current article we briefly
examine recent data regarding different lipid-lowering
approaches (non-statin-based or combined strategies) in
patients with mixed atherogenic dyslipidemia.
Fibrates: new evidences from HHS, BIP extensions and 
FIELD
Fibrates have been used in clinical practice for more than
four decades due to their ability substantially to decrease
triglyceride levels, to increase HDL-cholesterol levels and
in addition to reduce LDL-cholesterol moderately but sig-
nificant [9].
Due to their beneficial effects on glucose and lipid metab-
olism, PPAR's alpha agonists (fibrates) are good potential
candidates for reducing the risk of myocardial infarction
(MI) in subjects with metabolic syndrome and diabetes
[10-12]. Although less clinical intervention studies have
been performed with fibrates than with statins, there are
evidences indicating that fibrates may reduce risk of cardi-
ovascular disease and particularly non-fatal MI [13-19].
Interestingly, reduction of cardiovascular disease with two
of the fibric acid derivates – gemfibrozil and bezafibrate –
was more pronounced in patients displaying baseline
characteristics very similar to metabolic syndrome defini-
tions [13,14,20].
There have been no direct head-to-head comparisons of a
statin with a fibrate in any clinical endpoint trial. How-
ever, compared with statins, fibrates appear to more selec-
tively target the therapeutic goals in obese individuals
with features of insulin resistance and metabolic syn-
drome (i.e. with near-goal LDL-cholesterol and inappro-
priate HDL-cholesterol and triglyceride levels).
Gemfibrozil: confirmed long-term efficacy
The primary-prevention trial Helsinki Heart Study (HHS)
showed that treatment with gemfibrozil led to a signifi-
cant reduction in major cardiovascular events [13].
Regarding secondary prevention, in the VA-HIT study
(Veterans Affairs High-density lipoprotein cholesterol
Intervention Trial) – which included 30% of diabetic
patients – gemfibrozil reduced the occurrence of major
cardiovascular events by 22 % [14]. Similarly, reduction
of cardiovascular disease with gemfibrozil was more pro-
nounced in patients displaying above three of the features
of metabolic syndrome [21,22].
The 18-year results from the Helsinki Heart Study shows
that patients in the original gemfibrozil group had a 23%
lower risk of CAD mortality compared with the original
placebo group. But those in the highest tertile of both
body-mass index and triglyceride level at baseline had the
most dramatic risk reductions with gemfibrozil – 71% for
CAD mortality and 33% for all-cause mortality [23].
These results are entirely consistent with the original pos-
itive results of HHS and are strongly supported by the
findings of VA-HIT.
Fenofibrate: disappointing results of the FIELD
The recent Fenofibrate Intervention and Event Lowering
in Diabetes (FIELD) study (24 investigated the effects of
fenofibrate on cardiovascular events in type 2 diabetes
patients. This was a multinational, randomized, double-
blind, placebo-controlled trial in 9795 subjects aged 50 to
75 years of age with type 2 diabetes who were not pre-
scribed statin therapy at study entry. The primary end-
point was coronary events (CAD death or nonfatal MI).
The prespecified endpoint for subgroup analyses was car-
diovascular events (cardiovascular death, MI, stroke, and
coronary and carotid revascularization procedures). After
5 years, fenofibrate-treated patients had a nonsignificant
11% reduction in the incidence of the primary endpoint,
nonfatal myocardial infarction, or CAD death (5.2%
event rate for the fenofibrate group compared with 5.9%
for the placebo group; P = 0.16). Fenofibrate treatmentCardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
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did, however, reduce the incidence of the broader total
cardiovascular events endpoint (a prespecified secondary
endpoint) by 11% (P = 0.035). Fenofibrate reduced the
incidence of most other prespecified endpoints of mac-
rovascular disease, including nonfatal MI events by 24%
(P  = 0.01), coronary revascularizations by 21% (P  =
0.003), and all revascularizations by 20% (P = 0.001).
Fenofibrate treatment had a particularly beneficial effect
in patients that had no prior CAD. In this primary preven-
tion population (78% of the total population), fenofi-
brate reduced the incidence of the primary endpoint
(CAD events) by 25% (P = 0.014) and the incidence of
total cardiovascular events by 19% (P = 0.004). In addi-
tion, fenofibrate unexpectedly showed statistically signifi-
cant reductions in several endpoints, suggesting that
microvascular benefit was provided by this treatment.
These included a reduction in the requirement for laser
retinopathy (5.2% vs. 3.6%, for a 30% reduction; P =
0.0003) and a reduction in albuminuria (2.5% absolute
reduction and 1.2% regression; P = 0.002).
The FIELD study design allowed for statin therapy or other
lipid-lowering drugs to be added at any time after rand-
omization to either the fenofibrate arm or the placebo
arm. The average use of other lipid-lowering therapies
(mainly statins) was 17% in the placebo patients and 8%
in the fenofibrate patients (P < 0.0001). Significant differ-
ences existed also in the use of other in-treatment thera-
pies between the two treatment arms, including
angiotensin- converting enzyme (ACE) inhibitors (P  =
0.003), beta-blockers (P = 0.01), diuretics (P = 0.006),
and coronary revascularization procedures (P = 0.003),
with the greater use always occurring in placebo patients.
There was a continual increase in statin use through the
course of the study, and by the end of the study the statin
drop-in rate was 36% in the placebo patients and 19% in
the fenofibrate patients. Initiation of statin therapy and
other secondary preventive therapies such as aspirin, ACE
inhibitors, and beta-blockers also occurred at higher rates
in patients with a prior history of CAD compared with
patients with no prior history of CAD. The differential use
of statins and other evidence-based therapies significantly
attenuated the benefits of fenofibrate therapy. Adjustment
for statin use revealed a pronounced reduction of total
cardiovascular events.
A second explanation for the negative outcome of FIELD
related to the change in lipids with fenofibrate, which was
considerably less than expected for HDL cholesterol: it
was increased by just 5% (compare, for example, with
18% increasing of HDL cholesterol by bezafibrate in the
Bezafibrate Infarction Prevention (BIP) trial)).
Bezafibrate: emerged benefits in metabolic syndrome
Bezafibrate, in comparison with other fibrates, has an
unique characteristic profile of action since it activates all
three PPAR subtypes (alpha, gamma and delta) at compa-
rable doses [25-27]. Therefore, bezafibrate operates as a
pan-agonist for all three PPAR isoforms. In two old stud-
ies bezafibrate decreased the rate of progression of coro-
nary atherosclerosis and decreased coronary event rate
[15,16]. In another large trial in 1568 men with lower
extremity arterial disease, bezafibrate reduced the severity
of intermittent claudication [17]. In general, the incidence
of coronary heart disease in patients on bezafibrate has
tended to be lower, but this tendency did not reach statis-
tical significance. However, bezafibrate had significantly
reduced the incidence of non-fatal coronary events, partic-
ularly in those aged <65 years at entry, in whom all coro-
nary events may also be reduced. In the BIP study an
overall trend of a 9.4% reduction of the incidence of pri-
mary end point (fatal or non-fatal myocardial infarction
or sudden death) was observed. The reduction in the pri-
mary end point in 459 patients with high baseline triglyc-
erides (200 mg/dL) was significant [18].
Most recent extensions of the BIP trial give further support
to the hypothesis that patients with insulin-resistant syn-
dromes such as diabetes or metabolic syndrome might be
the ones to derive the most benefit from therapy with
fibrates [20,28-30]. Bezafibrate can reduce the incidence
of MI in patients with metabolic syndrome. Overall, bez-
afibrate treatment was associated with reduced risk of any
MI and non-fatal MI with HR (CI) respectively 0.71
(0.54–0.95) and 0.67 (0.49–0.91). The cardiac mortality
risk tended to be lower on bezafibrate (HR 0.74, CI 0.54–
1.03). This trend persisted in patients with augmented fea-
tures of metabolic syndrome(at least 4 risk factors for met-
abolic syndrome); of note, a marked reduction in cardiac
mortality was observed among these patients on bezafi-
brate (HR 0.44, CI 0.25–0.80).
Measurements obtained during placebo treatment within
BIP trial demonstrated a natural history of progressive
increasing of insulin resistance over long-term follow-up
[28]). These unfavorable longitudinal changes were
stopped when patients used bezafibrate. In addition,
reduced incidence of type 2 diabetes in patients on bezaf-
ibrate has been demonstrated [29,30]. These new data
raise the intriguing possibility that bezafibrate and other
fibrates may eventually prove to be clinically useful for
conditions other than dyslipidemia [31].
The factor that dominates in overweight-related metabolic
syndrome is the permanent elevation of plasma free fatty
acids (FFA) and the predominant utilization of lipids by
the muscle inducing a diminution of glucose uptake and
insulin resistance. Currently, an insulin-resistant state – asCardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
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the key phase of metabolic syndrome – constitutes the
major risk factor for development of macrovascular com-
plications [32-35].
On the basis of the current concept of the evolution of adi-
pogenesis via PPAR modulation toward insulin resistance
and atherothrombotic macrovascular complications
(including MI), the decreasing of plasma FFA and improv-
ing of insulin sensitization by PPAR agonists seems to be
a logical and valuable goal for therapy.
It is important to note that on a whole-body level, lipid
and glucose metabolisms interact intimately. Briefly,
PPAR alpha is activated by fibric acids (e.g. bezafibrate)
and form heterodimers with the 9-cis retinoic acid recep-
tor (RXR). These heterodimers bind to peroxisome prolif-
erator response elements, which are located in numerous
gene promoters and increase the level of the expression of
mRNAs encoded by PPAR alpha target genes. Bezafibrate
reduces triglyceride plasma levels through increases in the
expression of genes involved in fatty acid-beta oxidation
and by decrease in apolipoprotein C-III gene expression.
Fibric acids increase HDL-C partly by increasing apolipo-
protein A-I and apolipoprotein A-II gene expression. Their
triglyceride-lowering and HDL-C raising effects lead to
decreased systemic availability of fatty acid, diminished
fatty acid uptake by muscle with improvement of insulin
sensitization and reduced plasma glucose level [36-39].
Evidence also suggests that there is a 'fibrate effect' that
mediates the reduction in CAD risk beyond the favorable
impact of these agents on HDL-C levels. This last notion
is consistent with the pleiotropic effects of fibrates which
are known to be related to their mechanisms of action
[40]. Through PPAR alpha, fibrates have a significant
impact on the synthesis of several apolipoproteins (apo)
and enzymes of lipoprotein metabolism as well as on the
expression of several genes involved in fibrinolysis and
inflammation. Such changes contribute to improve the
catabolism of triglyceride-rich lipoproteins, leading to a
substantial increase in HDL-C levels accompanied by a
shift in the size and density of LDL particles: from small,
dense LDL particles to larger, more buoyant cholesteryl
ester-rich LDL. These observations becomes particularly
important given the dramatic increase in obesity, diabe-
tes, and metabolic syndrome, conditions associated with
low HDL and high triglyceride levels and small, dense
LDL particles, the lipid profile for which fibrates would
seem to be ideally suited [31].
However, different fibrates may have a somewhat differ-
ent spectrum of effects. Pooled together evidence suggests,
that gemfibrozil and bezafibrate have optimum cardio-
vascular benefit in metabolic syndrome and/or other
appearances of insulin resistance.
Nicotinic acid
Nicotinic acid (or niacin) has beneficial effects on all tra-
ditional blood lipid and lipoprotein fractions, particularly
for increasing high-density lipoprotein (HDL)-cholesterol
and reducing lipoprotein(a). Nicotinic acid has been used
for the treatment of dyslipidemia since the 1950's, but the
mechanism of action has only recently been elucidated.
Niacin, a vitamin of the B complex which participates in
tissue respiration oxidation-reduction reactions, decreases
the fractional catabolic rate of apoA-I via  reduction in
hepatocytes uptake [41]. Increasing apoA-I would facili-
tate greater RCT by making apoA-I more bioavailable to
remove excess cellular cholesterol from the arterial wall
macrophage. Niacin also inhibits hepatic diacylglycerol
acyltransferase 2 (DGAT2) which is a key enzyme in the
synthesis of triglycerides destined for VLDL [42]. Nico-
tinic acid additionally inhibits adipose tissue lipolysis by
inhibiting hormone-sensitive triglyceride lipase [43]. It is
through this combination of action that nicotinic acid
exerts its changes upon lipid parameters – increased HDL,
lowered LDL and TG – and the clinical consequences of
these effects have been positively borne out in clinical tri-
als.
The benefits of niacin therapy upon cardiovascular events
and mortality was first demonstrated in the Coronary
Drug Project (CDP), a randomized, double-blind, pla-
cebo-controlled trial on 8,341 men with prior myocardial
infarction that was started in 1966 [44]. Significantly
fewer cardiovascular events and a mortality benefit were
seen at the conclusion of the original trial after 6 years of
follow-up, and these results persisted 15 years after the
initiation of niacin [45]. Niacin therapy, however, is
poorly tolerated by patients primarily because of skin
flushing. Of subjects taking immediate-release niacin
85% experience flushing [46]; in fact, 75% of patients in
the niacin arm of the CDP dropped out of the study [47].
The flushing issue has been ameliorated by the introduc-
tion of slow-release niacins – flushing for these products
is approximately 26% [46] – and pre-medication with
aspirin. However, slow-release niacins lead to hepatotox-
icity, which appear to be caused by metabolites of the
nicotinamide metabolic pathway.
New prolonged-release nicotinic acid designed to produce
less vasodilatory flushing than crystalline immediate-
release nicotinic acid and less hepatotoxicity than previ-
ous sustained-release formulations of nicotinic acid [48].
Despite the benefit of this therapy, patient adherence is
poor. Nicotinic acid has also been criticized for dysregula-
tion of glycemic control [49]: nicotinic acid therapy, par-
ticularly in large doses, can decrease insulin sensitivity
and increase plasma glucose levels [50,51]. Probably, this
effect for prolonged-release nicotinic acid is less than pre-
viously reported for crystalline nicotinic acid [52].Cardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
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Bile acid sequestrants
There are three most popular bile acid sequestrants:
cholestyramine, colesevelam, and colestipol. These drugs'
principal mechanism of action is the binding of bile acids
within the intestinal lumen thereby reducing the reab-
sorption of bile acids and available intrahepatic choles-
terol. Partial diversion of the enterohepatic circulation
using bile acid sequestrants depletes the endogenous bile
acid pool by approximately 40%, thus stimulating an
increase in bile acid synthesis from cholesterol, which
lowers low-density lipoprotein cholesterol by 15 to 26%.
The mechanism by which HDL is raised is through
increased intestinal production of apoA-I [53]. The largest
trial to study a bile acid sequestrant as monotherapy for
hypercholesterolemia was the Lipid Research Clinics Cor-
onary Primary Prevention Trial. This trial of 3,806 hyper-
cholesterolemic men without CAD found a 19 percent
reduction in the incidence of CAD in the men treated with
cholestyramine [54]. Bile acid sequestrants are not
absorbed by the intestine and thus have no systemic drug-
drug interactions, but may interfere with the absorption of
some drugs [55]. The use of bile acid sequestrants is lim-
ited by patient adherence as these drugs commonly cause
gastrointestinal side effects, especially constipation, and
require large and frequent dosing. The effect on HDL ele-
vation is usually negligible. Lastly, for the dyslipidemic
patient who concomitantly has high triglycerides, these
drugs have no beneficial effect.
Ezetimibe
Ezetimibe is a novel cholesterol absorption inhibitor that
blocks the translocation of dietary and biliary cholesterol
from the gastrointestinal lumen into the intracellular
space of jejunal enterocytes [56]. Similar to the bile acid
sequestrants, ezetimibe reduces intestinal cholesterol
absorption by binding to the apical cholesterol export
pumps ABC proteins. The ABC transporters are located in
the intestinal enterocytes brush border and promote
efflux of dietary cholesterol and plant sterols from entero-
cytes back into the intestinal lumen, thus limiting the
amount of absorbed cholesterol [57]. Experimental mod-
els suggest that ezetimibe, similar to other lipid-modify-
ing agents, results in reduced atherosclerosis; in apoE-
knockout mice, ezetimibe administration resulted in
reduced carotid and aortic atherosclerotic development
[58]. The coadministration of ezetimibe with a statin has
yet to be proven to have a morbidity or mortality advan-
tage over uptitration of statin monotherapy. Overall,
ezetimibe has a favourable drug-drug interaction profile,
as evidenced by the lack of clinically relevant interactions
between ezetimibe and a variety of drugs commonly used
in patients with hypercholesterolaemia. Ezetimibe does
not have significant effects on plasma levels of statins,
fibrates, digoxin, glipizide, warfarin and triphasic oral
contraceptives. Higher ezetimibe exposures were observed
in patients receiving concomitant ciclosporin, and
ezetimibe caused a small but statistically significant effect
on plasma levels of ciclosporin. Because treatment experi-
ence in patients receiving ciclosporin is limited, physi-
cians are advised to exercise caution when initiating
ezetimibe in the setting of ciclosporin coadministration,
and to carefully monitor ciclosporin levels.
CETP inhibition
Increasing HDL-cholesterol levels by pharmacological
inhibition of the CETP is currently under intense investi-
gation. Two small-molecule compounds, JTT-705 and
torcetrapib, have been shown to effectively increase HDL-
c levels in humans, without inducing clinically significant
side effects when used as monotherapy or combined with
statins [59,60]. Whether this approach will translate into
a reduction in risk of atherosclerotic disease has not yet
been established. Elevated HDL secondary to CETP defi-
ciency may not then be entirely atheroprotective. An inhi-
bition of CETP would allow the accumulation of lipid-
laden HDL, but not lipid-deficient HDL. One hypothesis
that could support the epidemiologic findings is that
although HDL is increased, more atherogenic low density
particles could accumulate, and if HDL is already lipid-
laden, there would be less lipid-deficient HDL to partici-
pate in RCT. Animal models suggest, however, that partial
inhibition of CETP results in reduced atherosclerosis.
Clinical trials of CETP inhibitors in humans have resulted
in impressive increases in HDL. Torcetrapib, a small mol-
ecule inhibitor of CETP, increased HDL by 46 to 106%
without significant change in other lipid parameters [61].
Another small molecule inhibitor JTT-705 increased HDL
by 34% with a modest 7% decrease in LDL [62]. Clinical
trials with hard cardiovascular endpoints are pending,
and an intravascular ultrasound (IVUS)-based imaging
endpoint study of torcetrapib is also underway.
Combined therapy: approaches to optimization lipid-
lowering managment
Whereas statins remain the drug of choice for patients
who need to achieve the LDL-C goal, fibrates, niacin or
bile acid sequestrants may represent the alternative inter-
vention for subjects with atherogenic dyslipidemia typical
for metabolic syndrome and an LDL-C already close to
goal values. In addition, the concomitant use of fibrates or
niacin seems to be attractive in patients whose LDL-cho-
lesterol is controlled by statin therapy but whose HDL-
cholesterol and/or triglyceride levels are still inappropri-
ate [63-67]. This strategy will be tested in the ongoing
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial [68]. Although like FIELD, fenofibrate is
used in ACCORD to treat diabetes, unlike the FIELD study
fenofibrate is not being used as monotherapy but only in
combination with simvastatin to compare with simvasta-
tin therapy alone. This design should largely avoid theCardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
Page 6 of 8
(page number not for citation purposes)
problem of off-trial drug use encountered in FIELD and at
the same time might solidify a role for fenofibrate as a spe-
cific adjunct to statin therapy in the treatment of diabetic
dyslipidemia [68].
Conclusion
Controlled clinical trials show similar or even greater car-
diovascular benefits from statins-based therapy in patient
subgroups with diabetes, impaired fasting glucose, and
metabolic syndrome, compared with overall study popu-
lations [69]. Therefore, statins are the drug of first choice
for aggressive lipid lowering actions and reducing risk of
coronary artery disease in these patients with combined
atherogenic dyslipidemia. However, current therapeutic
use of statins as monotherapy is still leaving many
patients with mixed atherogenic dyslipidemia at high risk
for coronary events and commonly insufficient to achieve
all lipid targets recommended by current guidelines. For
this reason, other approaches to treatment of combined
hyperlipidemia should be considered. Because fibrates,
niacin, ezetimibe and statins each regulate serum lipids by
different mechanisms, combination therapy may offer
particularly desirable benefits in patients with combined
hyperlipidemia.
A combination statin/fibrate or statin/niacin therapy may
be often necessary to control all lipid abnormalities in
patients with metabolic syndrome and diabetes ade-
quately, since fibrates and niacin provide additional
important benefits, particularly on triglyceride and HDL-
cholesterol levels. Thus, this combined therapy concen-
trates on all the components of the mixed dyslipidemia
that often occurs in persons with diabetes or metabolic
syndrome, and may be expected to reduce cardiovascular
morbidity and mortality.
Safety concerns about some fibrates such as gemfibrozil
may lead to exaggerate precautions regarding fibrate
administration and therefore diminish the use of these
agents. However, other fibrates (such as bezafibrate and
fenofibrate) appear to be safer and better tolerated [70-
76]. In addition, bezafibrate as pan-PPAR-activator has
clearly demonstrated beneficial pleiotropic effects related
to glucose metabolism and insulin sensitivity. Therefore a
proper co-administration of statins with other agents:
fibrates, niacin [77] or ezetimibe [78] – selected on basis
of their safety and effectiveness, could be more valuable in
achieving a comprehensive lipid control as compared
with statins monotherapy.
Abbreviations
ACE – angiotensin converting enzyme
ACCORD – Action to Control Cardiovascular Risk in Dia-
betes
ATP – Adult Treatment Panel
BIP – Bezafibrate Infraction Prevention
CAD – coronary artery disease
CETP – cholesteryl ester transfer protein
DM – diabetes mellitus
FIELD – Fenofibrate Intervention and Event Lowering in
Diabetes
FFA – free fatty acids
HDL – high-density lipoprotein
HHS – Helsinki Heart Study
LDL – low-density lipoprotein
MI – myocardial infarction
NCEP – National Cholesterol Education Program
PPAR – peroxisome proliferator activated receptor
VA-HIT – Veterans Affairs High-density lipoprotein cho-
lesterol Intervention Trial
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors have equally contributed in the conception
and drafting of the manuscript.
Acknowledgements
This work was supported in part by the Cardiovascular Diabetology 
Research Foundation (RA 58-040-684-1), Holon, Israel, and the Research 
Authority of Tel-Aviv University (Citernick grant 01250239).
References
1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC,
Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak
RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC; National Heart,
Lung and Blood Institute: AHA/ACC guidelines for secondary
prevention for patients with coronary and other atheroscle-
rotic vascular disease: 2006 update: endorsed by the
National Heart, Lung, and Blood Institute.  Circulation 2006,
113:2363-2372.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder
R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorv-
astatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus
moderate lipid lowering with statins after acute coronary
syndromes.  N Engl J Med 2004, 350:1495-504.
3. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD,
Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE,Cardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
Page 7 of 8
(page number not for citation purposes)
Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, A to
Z Investigators: Early intensive vs a delayed conservative sim-
vastatin strategy in patients with acute coronary syndromes:
phase Z of the A to Z trial.  JAMA 2004, 292:1307-1316.
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC,
Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating
to New Targets (TNT) Investigators: Intensive lipid lowering with
atorvastatin in patients with stable coronary disease.  N Engl
J Med 2005, 352:1425-1435.
5. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ,
Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: Incre-
mental Decrease in End Points Through Aggressive Lipid
Lowering (IDEAL) Study Group. High-dose atorvastatin vs
usual-dose simvastatin for secondary prevention after myo-
cardial infarction: the IDEAL study: a randomized controlled
trial.  JAMA 2005, 294:2437-2445.
6. Fisman EZ, Adler Y, Tenenbaum A: Statins research unfinished
saga: desirability versus feasibility.  Cardiovasc Diabetol 2005, 4:8.
7. Christopher CP: The IDEAL cholesterol: lower is better.  JAMA
2005, 294:2492-2494.
8. Pitt B: Low-density lipoprotein cholesterol in patients with
stable coronary heart disease – is it time to shift our goals?
N Engl J Med 2005, 352:1483-1484.
9. Tenenbaum A, Fisman EZ: Which is the best lipid-modifying
strategy in metabolic syndrome and diabetes: fibrates, stat-
ins or both?  Cardiovasc Diabetol 2004, 3:10.
10. Sacks FM, for the Expert Group on HDL Cholesterol: The role of
high-density lipoprotein [HDL] cholesterol in the prevention
and treatment of coronary heart disease: Expert Group rec-
ommendations.  Am J Cardiol 2002, 90:139-143.
11. Fruchart JC: Peroxisome proliferator-activated receptor-
alpha activation and high-density lipoprotein metabolism.
Am J Cardiol 2001, 88(12A):24N-29N.
12. Verges B: Clinical interest of PPARs ligands.  Diabetes Metab
2004, 30:7-12.
13. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Hut-
tunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart
Study: primary-prevention trial with gemfibrozil in middle-
aged men with dyslipidemia. Safety of treatment, changes in
risk factors, and incidence of coronary heart disease.  N Engl J
Med 1987, 317:1237-1245.
14. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas
FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfi-
brozil for the secondary prevention of coronary heart dis-
ease in men with low levels of high-density lipoprotein
cholesterol. Veterans Affairs High-Density Lipoprotein Cho-
lesterol Intervention Trial Study Group.  N Engl J Med 1999,
341:410-418.
15. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bez-
afibrate treatment over five years on coronary plaques caus-
ing 20% to 50% diameter narrowing (The Bezafibrate
Coronary Atherosclerosis Intervention Trial (BECAIT)).  Am
J Cardiol 1997, 8:1125-1129.
16. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mah-
mood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascu-
lar outcomes in type 2 diabetes. A double-blind placebo-
controlled study of bezafibrate: the St. Mary's, Ealing, North-
wick Park Diabetes Cardiovascular Disease Prevention
(SENDCAP) Study.  Diabetes Care 1998, 21:641-648.
17. Meade T, Zuhrie R, Cook C, Cooper J: Bezafibrate in men with
lower extremity arterial disease: randomised controlled
trial.  BMJ 2002, 325(7373):1139.
18. Secondary prevention by raising HDL cholesterol and reduc-
ing triglycerides in patients with coronary artery disease: the
Bezafibrate Infarction Prevention (BIP) study.  Circulation
2000, 102:21-27.
19. Diabetes Atherosclerosis Intervention Study Investigators: Effect of
fenofibrate on progression of coronary-artery disease in type
2 diabetes: the diabetes atherosclerosis intervention study, a
randomised study.  Lancet 2001, 357:905-910.
20. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S:
Bezafibrate for the secondary prevention of myocardial inf-
arction in patients with metabolic syndrome.  Arch Intern Med
2005, 165:1154-1160.
21. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Hei-
nonen OP, Frick MH: Joint effects of serum triglyceride and
LDL cholesterol and HDL cholesterol concentrations on cor-
onary heart disease risk in the Helsinki Heart Study. Implica-
tions for treatment.  Circulation 1992, 85:37-45.
22. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ,
Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovas-
cular disease: subgroup analysis from the Department of Veter-
ans Affairs high-density lipoprotein intervention trial (VA-HIT).
Arch Intern Med 2002, 162:2597-2604.
23. Tenkanen L, Manttari M, Kovanen P, Virkkunen H, Manninen V:
Gemfibrozil in the treatment of dyslipidemia: an 18-year
mortality follow-up of the Helsinki Heart Study.  Arch Intern
Med 2006, 166:743-748.
24. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P,
Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt
D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD
study investigators: Effects of long-term fenofibrate therapy on
cardiovascular events in 9795 people with type 2 diabetes
mellitus (the FIELD study): randomised controlled trial.  Lan-
cet 2005, 366:1849-1861.
25. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs:
from orphan receptors to drug discovery.  J Med Chem 2000,
43:527-550.
26. Berger J, Moller DE: The mechanisms of action of PPARs.  Annu
Rev Med 2002, 53:409-435.
27. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome
proliferator-activated receptors (PPAR) co-agonism: the
bezafibrate lessons.  Cardiovasc Diabetol 2005, 4:14.
28. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M,
Matas Z, Motro M, Behar S: Attenuation of progression of insu-
lin resistance in patients with coronary artery disease by bez-
afibrate.  Arch Intern Med 2006, 166:737-741.
29. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y,
Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome
proliferator-activated receptors ligand bezafibrate for pre-
vention of type 2 diabetes mellitus in patients with coronary
artery disease.  Circulation 2004, 109:2197-2202.
30. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D,
Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate
on incidence of type 2 diabetes mellitus in obese patients.
Eur Heart J 2005, 26:2032-2038.
31. Bloomfield HE: The role of fibrates in a statin world.  Arch Intern
Med 2006, 166:715-716.
32. Groop LC: Insulin resistance: the fundamental trigger of type
2 diabetes.  Diabetes Obes Metab 1999:S1-S7.
33. Tenenbaum A, Fisman EZ, Motro M: Metabolic syndrome and
type 2 diabetes mellitus: focus on peroxisome proliferator
activated receptors (PPAR).  Cardiovasc Diabetol 2003, 2:4.
34. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E,
Tuomilehto J, Salonen JT: The metabolic syndrome and total
and cardiovascular disease mortality in middle-aged men.
JAMA 2002, 288:2709-2716.
35. Fruchart JC, Staels B, Duriez P: The role of fibric acids in athero-
sclerosis.  Curr Atheroscler Rep 2001, 3:83-92.
36. Rovellini A, Sommariva D, Branchi A, Maraffi F, Montalto C, Gandini
R, Fasoli A: Effects of slow release bezafibrate on the lipid pat-
tern and on blood glucose of type 2 diabetic patients with
hyperlipidaemia.  Pharmacol Res 1992, 25:237-245.
37. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga
A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Oku-
mura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on
insulin sensitivity and insulin secretion in non-obese Japanese
type 2 diabetic patients.  Metabolism 2001, 50:477-480.
38. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt
AH: Severe hypertriglyceridemia with insulin resistance is
associated with systemic inflammation: reversal with bezafi-
brate therapy in a randomized controlled trial.  Am J Med 2002,
112:275-280.
39. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG: Lowering
of plasma glucose concentrations with bezafibrate in
patients with moderately controlled NIDDM.  Diabetes Care
1990, 13:855-863.
40. Despres JP, Lemieux I, Robins SJ: Role of fibric Acid derivatives in
the management of risk factors for coronary heart disease.
Drugs 2004, 64:2177-2198.
41. Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of
high-density lipoprotein apolipoprotein A-I but not choles-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cardiovascular Diabetology 2006, 5:20 http://www.cardiab.com/content/5/1/20
Page 8 of 8
(page number not for citation purposes)
terol ester by Hep G2 cells. Implication for reverse choles-
terol transport.  Arterioscler Thromb Vasc Biol 1997, 17:2020-2028.
42. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML:
Niacin noncompetitively inhibits DGAT2 but not DGAT1
activity in HepG2 cells.  J Lipid Res 2004, 45:1835-1845.
43. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offer-
manns S: PUMA-G and HM74 are receptors for nicotinic acid
and mediate its anti-lipolytic effect.  Nat Med 2003, 9:352-355.
44. The Coronary Drug Project Research Group: The Coronary Drug
Project: Design, Methods, and Baseline Results.  Circulation
1973, 47:1-50.
45. Canner PL, Furberg CD, McGovern ME: Benefits of niacin in
patients with versus without the metabolic syndrome and
healed myocardial infarction (from the Coronary Drug
Project).  Am J Cardiol 2006, 97:477-479.
46. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and
safety of high-density lipoprotein cholesterol-increasing
compounds: a meta-analysis of randomized controlled trials.
J Am Coll Cardiol 2005, 45:185-197.
47. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ: The
role of high-density lipoprotein cholesterol in the prevention
and possible treatment of cardiovascular diseases.  Curr Mol
Med 2006, 6:571-587.
48. McCormack PL, Keating GM: Prolonged-release nicotinic acid: a
review of its use in the treatment of dyslipidaemia.  Drugs
2005, 65:2719-2740.
49. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia
in non-insulin-dependent diabetes mellitus.  JAMA 1990,
264:723-726.
50. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth
JA, O'Sullivan AJ: Effects of nicotinic acid on insulin sensitivity
and blood pressure in healthy subjects.  J Hum Hypertens 2000,
14:567-572.
51. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA,
Chisholm DJ, Campbell LV: Nicotinic acid-induced insulin resist-
ance is related to increased circulating fatty acids and fat oxi-
dation but not muscle lipid content.  Metabolism 2003,
52:699-704.
52. Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-
release nicotinic acid on nonesterified fatty acid flux in the
metabolic syndrome with atherogenic dyslipidemia.  Am J Car-
diol 2005, 95:1309-1313.
53. Shepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, Lawrie TD:
The effects of cholestyramine on high density lipoprotein
metabolism.  Atherosclerosis 1979, 33:433-444.
54. The Lipid Research Clinics Coronary Primary Prevention Trial
results. II: The relationship of reduction in incidence of coro-
nary heart disease to cholesterol lowering.  JAMA 1984,
251:365-374.
55. Insull W Jr: Clinical utility of bile acid sequestrants in the
treatment of dyslipidemia: a scientific review.  South Med J
2006, 99:257-273.
56. Toth PP, Davidson MH: Cholesterol absorption blockade with
ezetimibe.  Curr Drug Targets Cardiovasc Haematol Disord 2005,
5:455-462.
57. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Per-
evozskaya I, von Bergmann K: Inhibition of intestinal cholesterol
absorption by ezetimibe in humans.  Circulation 2002,
106:1943-1948.
58. Davis HR Jr, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent
cholesterol absorption inhibitor, inhibits the development of
atherosclerosis in ApoE knockout mice.  Arterioscler Thromb
Vasc Biol 2001, 21:2032-2038.
59. Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ:
Increasing high-density lipoprotein cholesterol through
cholesteryl Ester transfer protein inhibition: a next step in
the fight against cardiovascular disease?  Curr Drug Targets Car-
diovasc Haematol Disord 2005, 5:481-488.
60. Schaefer EJ, Asztalos BF: Cholesteryl ester transfer protein inhi-
bition, high-density lipoprotein metabolism and heart dis-
ease risk reduction.  Curr Opin Lipidol 2006, 17:394-398.
61. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG,
Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of
cholesteryl ester transfer protein on HDL cholesterol.  N Engl
J Med 2004, 350:1505-1515.
62. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinder-
man AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a
novel cholesteryl ester transfer protein inhibitor, JTT-705, in
humans: a randomized phase II dose-response study.  Circula-
tion 2002, 105:2159-2165.
63. Robins SJ: Cardiovascular disease with diabetes or the meta-
bolic syndrome: should statins or fibrates be first line lipid
therapy?  Curr Opin Lipidol 2003, 14:575-583.
64. Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ: Macrovas-
cular complications of metabolic syndrome: an early inter-
vention is imperative.  Int J Cardiol 2004, 97:167-172.
65. Fazio S, Linton MF: The role of fibrates in managing hyperlipi-
demia: mechanisms of action and clinical efficacy.  Curr Athero-
scler Rep 2004, 6:148-157.
66. Role of fibrates in reducing coronary risk: a UK Consensus.
Curr Med Res Opin 2004, 20:241-247.
67. Tenenbaum A, Fisman EZ, Motro M: Bezafibrate and simvastatin:
different beneficial effects for different therapeutic aims.  J
Clin Endocrinol Metab 2004, 89:1978.
68. Robins SJ, Bloomfield HE: Fibric acid derivatives in cardiovascu-
lar disease prevention: results from the large clinical trials.
Curr Opin Lipidol 2006, 17:431-439.
69. Verges B: Role for fibrate therapy in diabetes: evidence before
FIELD.  Curr Opin Lipidol 2005, 16:648-651.
70. Jokubaitis LA: Fluvastatin in combination with other lipid-low-
ering agents.  Br J Clin Pract 1996:28-32.
71. Gavish D, Leibovitz E, Shapira I, Rubinstein A: Bezafibrate and sim-
vastatin combination therapy for diabetic dyslipidaemia: effi-
cacy and safety.  J Intern Med 2000, 247:563-569.
72. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvo-
nen PJ: Plasma concentrations of active lovastatin acid are
markedly increased by gemfibrozil but not by bezafibrate.
Clin Pharmacol Ther 2001, 69:340-345.
73. Beggs PW, Clark DW, Williams SM, Coulter DM: A comparison of
the use, effectiveness and safety of bezafibrate, gemfibrozil
and simvastatin in normal clinical practice using the New
Zealand Intensive Medicines Monitoring Programme
(IMMP).  Br J Clin Pharmacol 1999, 47:99-104.
74. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L:
Effects of baseline level of triglycerides on changes in lipid
levels from combined fluvastatin + fibrate (bezafibrate,
fenofibrate, or gemfibrozil).  Am J Cardiol 2003, 92:794-797.
75. Farnier M: Combination therapy with an HMG-CoA reductase
inhibitor and a fibric acid derivative: a critical review of
potential benefits and drawbacks.  Am J Cardiovasc Drugs 2003,
3:169-178.
76. Shek A, Ferrill MJ: Statin-fibrate combination therapy.  Ann Phar-
macother 2001, 35:908-917.
77. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ,
Friedewald W: Fifteen year mortality in Coronary Drug
Project patients: long-term benefit with niacin.  J Am Coll Car-
diol 1986, 8:1245-1255.
78. Toth PP, Davidson MH: Simvastatin plus ezetimibe: combina-
tion therapy for the management of dyslipidaemia.  Expert
Opin Pharmacother 2005, 6:131-139.